SEARCH RESULT

Total Matching Records found : 105

Most big patented drugs skip India -Rupali Mukherjee

-The Times of India Big pharma may be crying hoarse over India's "weak'' intellectual property environment, but over the past five years or so, they have introduced only a handful of their patented blockbusters in the country. That's not all. The contribution of patented drugs in the Rs 72,000-crore pharma retail market is not even 1%, indicating that multinationals have been traditionally slow and have a poor track record in introducing...

More »

Patent justice-Sakthivel Selvaraj

-The Hindu     Drug patents are designed to create profits that enable more research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...

More »

Whistle blower Ashok Khemka in Robert Vadra-DLF land deal transferred for 44th time-Prashant Krar

-The Economic Times CHANDIGARH: Haryana government today transferred whistleblower in Robert Vadra-DLF land deal, Ashok Khemka, Haryana IAS officer to department of Archives within six months of his recent posting as managing director of Haryana Seeds Development Corporation. The latest transfer of Khemka, second in last few months and 44th in all, is seen as a bid to avoid further threat to image of the Congress government that has taken beating after...

More »

Novartis order may force pharma MNCs to change

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...

More »

A just order

-The Hindu The Supreme Court order rejecting a plea to grant patent protection for Glivec, a cancer-fighting drug from Novartis, is a landmark. It will greatly strengthen the quest for access to affordable medicines in India. The decision affirms the idea that a patent regime loses its social relevance when a drug is priced beyond the reach of the vast majority of a country's people. That pharmaceutical companies employ high pricing...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close